Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

The BOLERO-2 trial demonstrated that adding everolimus to exemestane substantially improved clinical benefit with acceptable safety in postmenopausal women with HR+ breast cancer relapsing/progressing on a nonsteroidal aromatase inhibitor. Incidences and severities of everolimus-related toxicity were consistent with other oncology settings, and were manageable using established strategies.

• Publication year

  2014

• Venue

  Annals of Oncology

• Publication date

  2014-03-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdu009PMID 24615500PMCID 3969554
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

  2013cited by this paper
• Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

  2013cited by this paper
• 1st International consensus guidelines for advanced breast cancer (ABC 1).

  2012cited by this paper
• International consensus guidelines for advanced breast cancer ( ABC 1 )

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

  2012cited by this paper
• BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.

  2012cited by this paper
• Everolimus for Advanced Pancreatic Neuroendocrine Tumors

  2012cited by this paper
• Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

  2012cited by this paper
• Everolimus for advanced pancreatic neuroendocrine tumors.

  2011cited by this paper
• S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.

  2011cited by this paper
• Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

  2010cited by this paper
• Phase 3 trial of everolimus for metastatic renal cell carcinoma

  2010cited by this paper
• Phase III Trial of Everolimus in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from RECORD-1

  2010cited by this paper
• Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

  2009cited by this paper
• Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

  2008cited by this paper
• Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.

  2007cited by this paper
• Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations.

  2006cited by this paper
• Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer

  2005cited by this paper
• Common Terminology Criteria for Adverse Events v3.0 (CTCAE)

  2003cited by this paper

• Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer

  2026cites this paper
• Everolimus Delivery via Lignin Nanoparticles Enhances Antitumor Activity in Hormone Receptor-Positive Breast Cancer

  2026cites this paper
• A Phase II, Multicenter, Randomized, Double-Blind Study to Assess the Tolerability of Escalating Induction Doses of Everolimus in Patients with Metastatic Breast Cancer (DESIREE)

  2025cites this paper
• Association Between Daily Timing of Everolimus and Survival in High‐Risk HR+/HER2− Early Breast Cancer: A Sub‐Analysis of the UCBG‐UNIRAD Trial

  2025cites this paper
• Clinical outcomes of everolimus in patients with hormone receptor positive breast cancer: a real-world analysis.

  2025cites this paper
• The Role of Precision Dosing and Therapeutic Drug Monitoring in Precision Oncology: A Single-centre Experience with Everolimus

  2025influential citation
• Low-dose vs standard-dose everolimus combined with endocrine therapy in patients with HR-positive, HER2-negative advanced breast cancer: A multicenter real-world study

  2025cites this paper
• Hormonrezeptor-positives, HER2-negatives Mammakarzinom: Moderne Therapiekonzepte bei metastasierter Erkrankung

  2024cites this paper
• Cardiovascular complications of ribociclib in breast cancer patients.

  2024cites this paper
• Quality by Design-Steered Development of Stealth Liposomal Formulation of Everolimus: A Systematic Optimization and Evaluation.

  2024cites this paper
• Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2− breast cancer

  2024influential citation
• Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701).

  2023cites this paper
• Safety of Sirolimus in Patients with Tuberous Sclerosis Complex under Two Years of Age—A Bicenter Retrospective Study

  2023cites this paper
• Relationship Between Daily Dose of Everolimus and Treatment Effect in Patients With Luminal HER2-negative Metastatic Breast Cancer

  2023cites this paper
• Cardiac Toxicity From Adjuvant Targeting Treatment for Breast Cancer Post-Surgery

  2022cites this paper
• Oral Oncolytics: Using Remote Technology to Improve Access, Operational Efficiency, and Satisfaction.

  2022cites this paper
• Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer

  2022cites this paper
• A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

  2022cites this paper
• Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES

  2021cites this paper
• Therapeutische Grundlagen in der gynäkologischen Onkologie

  2021cites this paper
• Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome

  2021cites this paper
• Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer

  2021cites this paper
• Cardiovascular toxicity of breast cancer treatment: an update

  2021cites this paper
• Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications

  2020cites this paper
• Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

  2020cites this paper
• Everolimus-related pneumonitis in metastatic breast cancer patients: Incidence, radiographic patterns and relevance to clinical outcome.

  2020cites this paper
• Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis

  2020cites this paper
• PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane

  2020cites this paper
• Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers

  2020cites this paper
• Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis

  2019cites this paper
• Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients

  2019cites this paper
• A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types

  2019cites this paper
• High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane

  2019cites this paper
• OTT_A_195121 9669..9683

  2019cites this paper
• Therapeutic drug monitoring of Everolimus in oncology: evidences and perspectives.

  2019cites this paper
• Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.

  2019cites this paper
• Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

  2019cites this paper
• Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study

  2019cites this paper
• Cardiovascular sequelae of breast cancer treatments: A review.

  2018cites this paper
• Drug discovery targeting the mTOR pathway.

  2018cites this paper
• Prevention of Stomatitis

  2018cites this paper
• Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients

  2018cites this paper
• Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis.

  2018cites this paper
• Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.

  2018influential citation
• Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review.

  2018cites this paper
• Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.

  2018cites this paper
• Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.

  2018cites this paper
• A pharmacological rationale for improved everolimus dosing in oncology and transplant patients

  2018cites this paper
• Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management

  2018cites this paper
• Bone-Targeted Therapies in Cancer-Induced Bone Disease

  2018cites this paper
• Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor–positive and Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in Japan

  2018cites this paper
• Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

  2018cites this paper
• Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety

  2018cites this paper
• Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer

  2018cites this paper
• Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial

  2018cites this paper
• Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

  2018cites this paper
• Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer.

  2017cites this paper
• Advances in the treatment of advanced oestrogen-receptor-positive breast cancer.

  2017cites this paper
• Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study

  2017cites this paper
• Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.

  2017cites this paper
• Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

  2017cites this paper
• Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells

  2017cites this paper
• Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.

  2017cites this paper
• Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

  2017influential citation
• Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

  2017cites this paper
• Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial

  2017cites this paper
• New agents for endocrine resistance in breast cancer.

  2017cites this paper
• Breast cancer treatment-induced cardiotoxicity

  2017cites this paper
• Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study

  2017cites this paper
• Over-treatment in metastatic breast cancer.

  2017cites this paper
• Prevention and treatment options for mTOR inhibitor-associated stomatitis

  2017cites this paper
• New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

  2017cites this paper
• Community pharmacist–led telephone follow-up enabled close management of everolimus-induced adverse events in an outpatient with metastatic breast cancer

  2017cites this paper
• Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure‐effect relationship

  2017cites this paper
• Optimizing Quality of Life in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: Treatment Options and Considerations

  2017cites this paper
• Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer

  2017cites this paper
• Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview

  2017cites this paper
• Perspective d’un suivi thérapeutique pharmacologique de l’évérolimus en cancérologie ? Résultats d’une étude exploratoire de la relation concentration-effet de l’évérolimus

  2017cites this paper
• Diabetology and oncology meet in a network model: union is strength

  2016cites this paper
• The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions

  2016cites this paper
• Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study

  2016cites this paper
• Safety of mTOR inhibitors in breast cancer

  2016cites this paper
• Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2− Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy

  2016cites this paper
• Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer

  2016cites this paper
• The therapeutic potential of mTOR inhibitors in breast cancer.

  2016cites this paper
• Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.

  2016cites this paper
• mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials

  2016cites this paper
• Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.

  2016cites this paper
• Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

  2016cites this paper
• A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients

  2016cites this paper
• Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

  2016cites this paper
• Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

  2016cites this paper
• Updates in the Use of the mTOR Inhibitor Everolimus in Advanced Breast Cancer

  2016cites this paper
• Management of mammalian target of rapamycin inhibitor–associated noninfectious pneumonitis in advanced breast cancer: A nursing perspective

  2016influential citation
• Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.

  2016cites this paper
• Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer

  2016cites this paper
• CE: A Review of Common Oral Treatments for Breast Cancer Improving Patient Safety in Nononcology Settings

  2016cites this paper
• Current management of mTOR inhibitor-associated stomatitis

  2015cites this paper
• Epithelial to mesenchymal transition is associated with rapamycin resistance

  2015cites this paper
• Impact of Informative Censoring on Statistics Used in the Validation of Surrogate Endpoints in Oncology

  2015cites this paper